Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.

Citation data:

Nature immunology, ISSN: 1529-2916, Vol: 18, Issue: 6, Page: 694-704

Publication Year:
Usage 16
Abstract Views 15
Link-outs 1
Captures 1
Readers 1
Mentions 3
News Mentions 2
Blog Mentions 1
Social Media 7
Tweets 7
Citations 1
Citation Indexes 1
10.1038/ni.3716, 10.3410/f.727471210.793533456
Katerndahl, Casey D S, Heltemes-Harris, Lynn M, Willette, Mark J L, Henzler, Christine M, Frietze, Seth, Yang, Rendong, Schjerven, Hilde, Silverstein, Kevin A T, Ramsey, Laura B, Hubbard, Gregory, Wells, Andrew D, Kuiper, Roland P, Scheijen, Blanca, van Leeuwen, Frank N, Müschen, Markus, Kornblau, Steven M, Farrar, Michael A Show More Hide
Springer Nature, Faculty of 1000, Ltd.
Immunology and Microbiology
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
The transcription factor STAT5 has a critical role in B cell acute lymphoblastic leukemia (B-ALL). How STAT5 mediates this effect is unclear. Here we found that activation of STAT5 worked together with defects in signaling components of the precursor to the B cell antigen receptor (pre-BCR), including defects in BLNK, BTK, PKCβ, NF-κB1 and IKAROS, to initiate B-ALL. STAT5 antagonized the transcription factors NF-κB and IKAROS by opposing regulation of shared target genes. Super-enhancers showed enrichment for STAT5 binding and were associated with an opposing network of transcription factors, including PAX5, EBF1, PU.1, IRF4 and IKAROS. Patients with a high ratio of active STAT5 to NF-κB or IKAROS had more-aggressive disease. Our studies indicate that an imbalance of two opposing transcriptional programs drives B-ALL and suggest that restoring the balance of these pathways might inhibit B-ALL.

This article has 0 Wikipedia mention.